

**Freedom of Information Request**

**Ref: 22-373**

13 July 2022

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

**In the past 3 months, how many Breast Cancer patients (any stage) were treated with:  
Abemaciclib monotherapy**

Zero.

**Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)**

We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital.

**Tamoxifen monotherapy**

We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital.

**Abemaciclib + Tamoxifen**

We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital.

**Abemaciclib + Tamoxifen + Goserelin**

We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital.

**Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) + Goserelin  
Goserelin:**

Abemaciclib + Aromatase Inhibitor 9

Goserelin We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital

**Aromatase inhibitor + Goserelin**

We do not hold this information, these drugs are usually prescribed by the GP rather than the

hospital.

**Tamoxifen+ Goserelin**

We do not hold this information, these drugs are usually prescribed by the GP rather than the hospital.

**How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

**Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**

**Atezolizumab +Nab-paclitaxel/Paclitaxel**

**Pembrolizumab**

**Sacituzumab Govitecan**

**Parp Inhibitors (Olaparib/Talazoparib)**

**Eribulin as a single agent or in combination**

**Capecitabine as a single agent**

**Platinum (e.g. carboplatin or cisplatin) as a single agent**

**Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**

**Taxane and/or Anthracycline in combination**

**Any other active systemic anti-cancer therapy**

We do not hold this information. The Trust does not record ER/PR/HER2 status in our e-prescribing system

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer  
University Hospitals Bristol and Weston NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**